TRYP Therapeutics has announced that the first patient has been dosed in the Company’s Phase II clinical trial for its lead candidate, TRP-8802. In combination with psychotherapy, TRP-8802 is intended to serve as a potential treatment for Binge Eating Disorder.
Category Press Release
Published in Microdose Psychedelic Insights
Companies Featured
Tryp TherapeuticsTryp Therapeutics is a clinical stage drug development company developing psilocybin products for various diseases/disorders including fibromyalgia.